Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine in Autoimmune and Subacute Thyroiditis
NCT07571681Phase 3Recruiting
- Sponsor
- Mansoura University
- Start
- Jun 2026
- Primary completion
- Jul 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
Phase 3, randomised trial of colchicine in Hashimoto's thyroiditis and subacute thyroiditis (SAT) (3 arms), sponsored by Mansoura University. Primary endpoints: C-Reactive Protein at 6 months, Erythrocyte Sedimentation Rate at 6 months and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
colchicine
03
Conditions
Hashimoto's thyroiditissubacute thyroiditis (SAT)
Beyond the preview
Go deeper on NCT07571681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07571681.